Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I’m leaning that way also but trashing our investment serves no good purpose to anyone. You are correct the Dr. has not been truthful to his investors…let’s hope he changes his ways 😀
Agree - IF* I were to do that it would be generally speaking. I wouldn’t mention the clinic.
I mean, generally speaking the Dr. is a lying scumbag lol
Fasctrack I get it. Best thing 2 do is nothing. Do U think I am happy? No one is so just
wait for the next run & bail. I honestly believe it will be soon GLTA
7 years ya should have made some money. I have also and bought from .0012 and up made money on couple of runs to .07 so it has not been alll bad ..let’s hope he does the right thing and move the company along …
So what do you suggest we do? Would you have us be sheep and drink the Kool Aid? I have been invested here for 7 years....yeah I know shame on me for being an idiot and buying into his BS. At what point do we say enough with the BS? 7 years of BS PRs and not one announcement has come to fruition in any material sense. Name one...I dare you. Do you think that is reasonable? Do you think that is acceptable performance for a CEO of a publically held company? I think he has very much exceeded his authority by transferring the distribution rights to his privately owned company, by entering into a lucrative distribution contract with his privately owned company, and by awarding himself 100,000,000 shares. I'd vote to fire him. I wouldn't hire him to run the local McDonalds drive through line. I'd sell but I am underwater on this dog with fleas. You need to wake up; the thought or hope of him pulling a rabbit out of his hat at this point is just a pipe dream.
Wow.. glad I chose not to invest in this
I would be careful not to defame his separate clinical practice. You'll be stuck defending a defamation claim and he'll use VDRM monies to go after you.
Just keep bashing your investment that's smart
Maybe posting Google Reviews to his clinic about his unethical business practices ?
I want the FULL capital loss, not this -30% crap hahahahaa
I imagine several complaints have already been filed or will be very soon.
IR has pretty much gone radio silent. Not one tweet or PR in nearly 4 months. No activity online about the company anywhere. Then otiko gives himself $700k loan with no explanation. IR guy gets a ton of shares for literally doing nothing.
It's obvious now that they did not ship any products in March either. Without any news or explanations that back into their previous PRs and tweets, lawsuits will be warranted against them. IMO.
Hopeful they have something big coming, but as each day passes it seems more unlikely.
Honestly I'd really like to file a complaint against him with the SEC or a private complaint but I'm not sure what that gets us. He doesn't have voting control of the company so the shareholders could call a meeting; we could probably fire him if we wanted to....but who would run the company? All I know is that our current President is self-dealing and substantially underperforming and something needs to happen or he will simply continue as he is.
The Doc is completely unchecked and accountable to no one. He is motivated by greed and his own self-interest and seemingly (despite the 100,000,000 share award to himself) has no interest in growing shareholder value. So long as the stock trades and he has shares to deal, he's happy (doesn't care about dilution).
Was literally thinking of that this morning. He won’t pump this for probably a year or two now. Hope he loses the $700K in Vegas this weekend
Also think we should seriously consider filing a complaint
come on Dr. hurry up and spend that $700K so ya can throw out another pump & fluff and move this crap along. we long time shareholders can use a little $cash$ also 🙂
Worse case scenario, if I don’t get my money back, IGPK will get me rich at least
VitaStem needs detail insert with more info
I do give credit to Intent Sciences for having a visible footprint of actually earning their shares in the now-expired one year agreement. Obviously, no large, notable medical publication would cover a company with less than <$500 organic, annual sales, but they did what they could to try to change that.
1 crooked buyer in Nigeria & we're off
Sad and infuriating, but highly likely to be dead on. Again, sad and infuriating, there is not one documentable piece of counter evidence in financial reports, or in public domain, at this time. Great product possibilities are totally overwhelmed by nonperformance of CEO et al.
Hoping this spikes to .03 on nothing isn't a strategy and likely will not happen any time soon. There's far too many red flags here and Otiko and IR remain silent for the most part. Unfortunately, without any serious business announcements this will remain flat or keep declining to new lows.
I rather not to find out. Some truths are better not to be disclosed while holding. It could be catastrophic. Better keep it in the low and let ViaDerma spike again at least at 0.03 cents and GTFO
After a month, I received initial, acknowledgement response to my emails to IR (Rich), regarding ongoing discrepancy in licensing revenue reported in financial reports vs announced in official PRs. He stated he has been tied up on another project. I provided requested information. He stated he will find out. I will pass along, if and when, answer is received.
Now I believe you are high. It is alright, can you share your experience at the moment? Are you anxious? Was it crystal or ICE? Are you on acid?
Keep adding everyday , one day it will go 0.0014-18
So, in a nutshell, not sure why posted such if you won’t provide any substancial Intel. Anyways, you claim that we should trust in your word and the insider friend of your friend that is providing you that fictional intel and chill, right?
Darn, you are special.
Chuckles
Please not in green. Unreadable!
Not at all!!! What these big cases have to do with small time punks like us in the OTCM VDRM Dumbest Money’s club ?
Most straightforward examples of the many:
03/02/23 PR - state licensing expands to 11 states ($55K/mo)
- expansion to all 50 in next 12 months
10/24/23 PR - state licensing expanded to 14 states ($70K/mo)
- keep expanding throughout year
Actual licensing revenue recorded in financial reports has been 10 states ($50K/mo) throughout 2023 and 1Q24. IR (Rich) just ignores emails about the discrepancy between official PRs and official financial reports.
Never had a doubt of such, I agree with your thought as well. However, the issue is not the company but the CEO.
The CEO is the biggest concern and could potentially drive the company to the ground
"...& that will happen" Really?? Are you sure about that? What evidence are you relying upon to make that statement? Your gut? Your trick knee? A hunch? If you tell me you are simply trying to keep your chin up and remain position, I understand. But you certainly can't base that conclusion on any record of actual achievements because there are none. Otiko ought to be ashamed, not to mention fired and prosecuted for theft of company cash and for impersonating a CEO.
😂 😂 😂...........now it's about the PPS
Yet.........when that was mentioned several times before MR. SLOPPY said it wasn't. What a 🤡 😂 😢......
Yes but it's all about PPS & that will happen
Assume? What is PR'd and posted on Twitter etc VS what the Financials show should tell you all you need to know 😂 😂
Does anyone else feel like they’ve been misled and lied to?
Referring to a PR as lame....hmmm.... sounds like you may be a non-believer as well?
I feel we will get a P/R no matter how lame
and where are we supposed to go? no buying? no volume?
DB - When a CEO fails to give any PR or update as to why he failed his fiduciary duties in reporting for what he took the $700k loan for and for not incorporating any form of Interest or repayment schedule like with all the VDRM existing loans, than this comes off as very much the same situation as what Madoff did on that bigger level.
And trust me - I have many millions of PURCHASED SHARES AS reasons to be concerned and angry with Otiko!!!
Notice the none believers R all still here LOL
I get how someone who takes about 1hr/11min and magically turns it into TWO HOURS might not get it...
Always interesting and informative speaking to Rich(he's on two stocks I have large positions in), I've done it for about 10 years. My point, which I'm sure flew over many heads is I'm not sharing!
All wagers(any amount) are welcome for ANY challenges to anything I've ever said...the call/my background...? I don't lie/bullshit. Wager amount into escrow account and go from there?
It would seem folks would want info, but these are crazy daz with soy complicating things. Now, run off and have that soi-latte!
Pay no attention to the keyboard behind the curtain. Vitastem works the best especially clear and onward to whatever will utilize his technology. :)
He's 14 and found his Dad's computer again. He's a petulant child who needs a lot of attention. Send him to his room. Ignore him and he'll go away.
1 hr and 59 mins and the end result from that conversation was: VDRM WILL BE FINE? WOW… took 2 hrs to conclude the word, FINE. Must be complicated the situation
1hr 10min 59sec......Sure you did. What could be your motivation to post such nonsense? Are we supposed to be envious or maybe curious of your fictitious chat. "Probably not helpful, or maybe it was." What?
gib·ber·ish
['jib(?)riSH]
noun
unintelligible or meaningless speech or writing; nonsense:
"he talks gibberish"
Followers
|
619
|
Posters
|
|
Posts (Today)
|
3
|
Posts (Total)
|
74600
|
Created
|
10/27/08
|
Type
|
Free
|
Moderators |
ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.
The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.
This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.
The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.
A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.
The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.
Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.
In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.
We are developing products in the following fields of use;
Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.
Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.
Treats symptoms of Influenza which is a$4B/ year global market: Common
Diabetic foot wounds.
Per 3/8/18 PR: ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.
Per 12/7/17 PR: The Company has signed an MOU and will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinary uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments.
Per 1/23/18 PR: The Company has also a licensing and distribution agreement in place with its Canadian partners to produce a CBD Topical Serum, which has a 92% absorption rate powered by ViaDerma's Patent Pending Dual Carrier Technology. The CBD and Terpene profile (enriched with specific essential oils and vitamins C, and D) is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. The serum has anti-inflammatory, anti-bacterial, and chronic pain relief properties that are absorbed by the skin and provide overall healing benefits. Sales are expected to begin in the first quarter of 2018 and are projected to generate approximately $2 million annual revenues.
The Patented Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2018.
CBD is a compound found in the Cannabis family of plants such as hemp. CBD is combined into our topical body care products like Elixr's Topical Balm, Serum, and Spray.
CBD is an antioxidant. Antioxidants protect our skin from damaging exposure to smoke, UV rays, and environmental pollutants. Cannabinoid receptors are located all throughout the skin, Topical CBD products interact with those receptors resulting homeostasis and healing. Studies show that CBD can help treat an array of skin conditions such as eczema, psoriasis, rosacea, and acne.
"What is Intellectual Property?" - A Publication by the World Intellectual Property Organization -
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |